Search clinical trials for: 0.1% AG-86893 Eye Drops

Total 621 results

Jeanette Du

Not yet recruiting

Low Dose Atropine for Symptomatic Vitreous Floaters

Vitreous Floaters

United States
Aciont Inc
National Eye Institute (NEI)

Completed

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

Non-Infectious Anterior Uveitis

United States
University of Birmingham
Cancer Research UK; Genmab

Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United Kingdom
The New York Eye & Ear Infirmary

Unknown

Post Intravitreal Injection Topical NSAID vs. Patching

Diabetic Macular Edema | Retinal Vein Occlusion | Neovascular Age-related Macular Degeneration

United States
Bayer

Completed

Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women

Healthy

Germany
Dar El Oyoun Hospital

Unknown

Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification

Cataract | Adverse Drug Event | Mydriasis

Egypt
University of Patras

Unknown

Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections

Stillborn Caesarean Section

Greece
Retina Vitreous Associates of Florida

Completed

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

Age-related Macular Degeneration | Central Retinal Vein Occlusion | Diabetic Macular Edema

United States
University Ghent

Terminated

Performance of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris (RGPIRIS_PA)

Low Vision

Belgium
Nordsjaellands Hospital

Recruiting

Combining Lidocaine and Ropivacaine for an Infraclavicular Brachial Plexus Nerve Block

Anesthesia, Local | Surgery | Brachial Plexus Block | Nerve Block | Forearm Fracture

Denmark
Wuhan Union Hospital, China

Recruiting

Esketamine Induction Intubation in ICU Patients.

Critically Ill Patients

China
The University of Texas Medical Branch, Galveston
National Institutes of Health (NIH); National Institute of General Medical... and other collaborators

Terminated

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Burns

United States
St. Jude Children's Research Hospital

Active, not recruiting

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
St. Jude Children's Research Hospital

Active, not recruiting

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Retinoblastoma

United States
KU Leuven
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital (RISQ-PATH)

Delirium | QT-prolongation

Belgium
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Washington
Pfizer

Completed

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam

Search clinical trials for: 0.1% AG-86893 Eye Drops

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations